Main Menu

BioMarin Pharmaceutical Inc.

(NASDAQ GS: BMRN)

Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. (“BioMarin”).  On October 25, 2021, a class action complaint was filed against BioMarin.  The complaint alleges that, between January 13, 2020 and September 3, 2021, defendants made materially false and misleading statements regarding BioMarin’s business, operations, and compliance policies.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was not as safe as BioMarin led investors to believe; (ii) BMN 307’s safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) thus, BioMarin overstated BMN 307’s clinical and commercial prospects; and (iv) as a result, BioMarin’s public statements were materially false and misleading.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 09/22/2022


* Indicates a required field.

Back to Page